← Leaderboards
Rick A Martin
Washington University
$353,976
Attributed
$353,976
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $217.7K · FY2005–07$250K$187.5K$125K$62.5K$0
'05
'06
'07
Funding mix
By agency
NIH$353,976 · 4
By mechanism
M01$353,976 · 4
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- Nancy L Bartlett$8,628,353
- Dineo Khabele$4,937,606
- Matthew J Walter$8,261,626
- Mark S Sands$13,206,849
- Timothy E Holy$21,059,469
Others in their field
Top investigators on “Adverse Event”
- James Dennis Neaton · Northwestern University$97,240,825
- Rose A Gubitosi-Klug · Case Western Reserve University$69,866,183
- Lisa P Jacobson · Johns Hopkins University$56,753,115
- Anne Christine Gelijns · Icahn School Of Medicine At Mount Sinai$54,912,059
- Robert J Gray · Dana-Farber Cancer Institute$49,428,707
- Susan Abushakra · Alzheon, Inc.$47,690,244
Research focus
Adverse EventAge-YearsAllogeneic Bone Marrow TransplantationBlindedCessation Of LifeChildhoodClinical ResearchClinical Trial Phase IiiComputer Retrieval Of Information On Scientific Projects DatabaseDouble-Blind MethodEnrollmentEnzymesEnzyme TherapyFundingGlycosaminoglycansGrantHome EnvironmentHuman SubjectHuman Therapy EvaluationIduronate-2-SulfataseInstitutionIntravenous AdministrationLabelLink
Grant awards (7)
TKT024 OPEN-LABEL EXTENSION$8,675
M01 · FY2007 · RR · contact PI
TKT024 OPEN-LABEL EXTENSION$80,381
M01 · FY2006 · RR · contact PI
EXTENDING THE PHENOTYPE OF NON-SYNDROMIC ORAL-FACIAL CLEFTS$2,499
M01 · FY2006 · RR · contact PI
PHASE III IDURONATE ERT FOR HUNTER SYNDROME$164,719
M01 · FY2005 · RR
TKT024 OPEN-LABEL EXTENSION$49,703
M01 · FY2005 · RR
EXTENDING THE PHENOTYPE OF NON-SYNDROMIC ORAL-FACIAL CLEFTS$3,287
M01 · FY2005 · RR
Phase III iduronate ERT for Hunter Syndrome$44,712
M01 · FY2004 · RR